Victor J Dzau

This inventor holds 30 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Cardiac Reprogramming. Top assignees: Leland Stanford Junior University, Duke University, The Brigham and Women's Hospital, Inc.. Active years: 1995-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Victor J Dzau. Retrieved from https://idiyas.com/inventor/victor-j-dzau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 9)

% Patents Active = 83.3

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 2.4

ph-index = 13

Forward Citations = 703(Granted Patents)

Location History:

Stanford, CA (US) (1996)
Los Altos, CA (US) (1998 - 1999)
Newton, MA (US) (1999 - 2003)
Los Altos Hills, CA (US) (1995 - 2004)
Durham, NC (US) (2009 - 2022)

Company Filing History:

12 out of 5,512

Leland Stanford Junior University

The Brigham and Women's Hospital, Inc.

patents

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

Areas of Expertise:

Cardiac Reprogramming

Cellular Reprogramming

Vascular Function

Paracrine Factors

Nucleic Acid Delivery

Histone Methyltransferase

VEGF Gene Transfer

Nitric Oxide Modulation

p53 Isoform

Mesenchymal Stem Cells

Therapeutic Compositions

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285444 - Multicistronic miRNA delivery for cardiac reprogramming (2025-04-29),

2. 11534464 - Direct reprogramming of cells to cardiac myocyte fate (2022-12-27),

3. 11512290 - Compositions and methods for cellular reprogramming (2022-11-29),

4. 10695378 - Direct reprogramming of cells to cardiac myocyte fate (2020-06-30),

5. 10130637 - Inhibition of histone methyltransferase for cardiac reprogramming (2018-11-20),

6. 9987309 - Direct reprogramming of cells to cardiac myocyte fate (2018-06-05),

7. 9353168 - Method of reducing cell death by administering a paracrine factor derived from a mesenchymal stem cell (2016-05-31),

8. 9279012 - Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell (2016-03-08),

9. 8703710 - Method of reducing cell death by administering a paracrine factor of a mesenchymal stem cell (2014-04-22),

10. 8129344 - Method of reducing cell death by administering a Sfrp polypeptide (2012-03-06),

11. 7638128 - Method of enhancing cardiac tissue repair by administering a SFRP polypeptide (2009-12-29),

12. 6821956 - Therapeutic use of cis-element decoys in vivo (2004-11-23),

13. 6774118 - Therapeutic use of CIS-element decoys in vivo (2004-08-10),

14. 6646006 - Enhancement of vascular function by modulation of endogenous nitric oxide production or activity (2003-11-11),

15. 6642208 - Enhancement of vascular function by modulation of endogenous nitric oxide production or activity (2003-11-04),

Title: **Victor J. Dzau: A Leader in Cardiovascular Innovations**

Introduction

Victor J. Dzau, based in Durham, NC, is a prominent figure in the field of cardiovascular medicine and cellular reprogramming. With an impressive portfolio of 29 patents, Dzau has significantly contributed to advancing cardiac health through innovative research and groundbreaking methodologies.

Latest Patents

Among his latest patents, Dzau introduced the "Direct reprogramming of cells to cardiac myocyte fate." This method promotes the conversion of cells into cardiomyocytic tissue by interacting with fibrotic tissue, such as scar tissue, utilizing microRNA oligonucleotides. His work facilitates the direct reprogramming of fibroblasts into cardiomyocytes or cardiomyoblasts. Additionally, he disclosed "Compositions and methods for cellular reprogramming," which encompasses innovative compositions that include various microRNAs and an activator of NFκB. This development provides methods for enhancing cardiomyocyte maturation in cells or subjects while also inhibiting this maturation when necessary.

Career Highlights

Dzau has built an impressive career, leveraging his expertise in cardiovascular medicine. He has held significant positions at esteemed institutions such as Leland Stanford Junior University and Brigham and Women's Hospital. His commitment to advancing medical science and patient care places him at the forefront of innovation in his field.

Collaborations

Throughout his career, Dzau has collaborated with notable professionals, including Gary H. Gibbons and Maria Mirotsou. These partnerships have fostered an environment of creativity and ingenuity, essential for pioneering advancements in cardiovascular research.

Conclusion

Victor J. Dzau's contributions to the field of cardiovascular medicine demonstrate a profound commitment to innovation and patient health. His extensive patent portfolio and collaborations with other experts underscore his role as a leader in advancing cardiac therapies. Through continued research and development, Dzau's work is likely to inspire future innovations that will significantly impact cardiovascular health.

Profile summary based on public USPTO records.